Drug Profile
Research programme: anti-malarial therapeutics - Mitsubishi Tanabe Pharma Corporation/Medicines for Malaria Venture
Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Griffith University; Medicines for Malaria Venture; Mitsubishi Tanabe Pharma Corporation; University of California, San Diego
- Class Antimalarials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Malaria in Japan
- 24 Mar 2021 Early research is still ongoing in Malaria in Japan (Medicines for Malaria Venture pipeline, March 2021)
- 28 Jun 2019 No recent reports of development identified for research development in Malaria in Japan